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Platelets undergo a secretory reaction in response to a variety of noncytotoxic 
stimuli. We have earlier suggested that this secretion of the vasoactive amines, 
histamine and serotonin, from platelet granules, is another manifestation of a 
general secretory mechanism to  be found in  most cells capable  of secreting 
granule-bound constituents  (1). Particular  similarities  were noted  among a 
number of ~mediator cells',  e.g.,  mast cells,  basophils,  platelets,  neutrophils, 
macrophages, and lymphocytes. A  common feature of these cell types is that 
their physiologic response to particular stimuli can be inhibited by organophos- 
phorus inhibitors of serine esterases. This raises the possibility that cell-associ- 
ated serine esterases are involved in these responses. The cell responses include 
not only secretion, e.g. from platelets (see below), mast cells (2, 3), neutrophils 
(1, 4), and basophils (5), but also neutrophil chemotaxis (6) and phagocytosis (7) 
and lymphocyte cytotoxicity (8, 9) and movement (10, 11). The organophospho- 
rus inhibitors used include diisopropylphosphonofluoridate (DFP) 1  and a variety 
ofphosphonate esters. They specifically and irreversibly inhibit serine esterases 
by phosphorylating the serine group in the active site of the enzyme (12). 
Use of organophosphorus inhibitors to examine the role of esterases in cell 
activation can provide two additional pieces of information. First, the structure 
of the phosphonate inhibitors determines their relative inhibitory activity for 
different serine esterases. This presumably reflects the ~goodness of fit' of the 
inhibitor for the active center of the enzyme, since the inhibitors are substrate 
analogs  which  phosphorylate the  serine  group  in  the  same  manner  as  the 
substrate  acylates it  (12,  13). This  property  has  been  used  to  demonstrate 
different inhibition specificities (activity-structure profiles) for trypsin, chymo- 
trypsin, Cls and acetylcholine esterase (13, 14). Phosphonates have been simi- 
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larly used to show that the esterase putatively involved in mast cell activation is 
different  from the  above four enzymes  (2),  and  that  there  are  two different 
esterases involved in the chemotactic response of neutrophils  (6). Since a major- 
ity of the serine esterases have endopeptidase as well as esterolytic activity, and 
the proteolytic properties are more likely to be involved in the cell activation 
(see reference 1 and Discussion), we have generally employed the term serine 
proteases for cell-associated activities. 
A second piece of information about the cell-associated serine proteases to be 
gained from use of the organophosphorus  inhibitors  relies on the observation 
that  the  inhibitors  have relatively little  activity,  if any,  on the  precursor or 
zymogen form of the enzymes (15).  This property has been used to show that 
some of the proteases involved in  cell responses  are in  fact activated by the 
stimulus and only then became inhibitable by the organophosphorus agent. In 
this way, it was shown that of the two esterases involved in neutrophil chemo- 
taxis, one was in an activated state and the other was in a precursor state and 
could be activated only by an interaction with the chemotactic stimuli (6). This 
has  led  to  the  concept  of stimulus-activatable  proteases  as  essential  compo- 
nents of the initiation of a  variety of cell responses (1). 
In previous work, we have described and characterized three unique noncyto- 
toxic  stimuli  which  cause  secretion  from  rabbit  platelets.  These  include  (a) 
platelet-activating  factor (PAF) which is a  low molecular weight material  re- 
leased from antigen-stimulated IgE-sensitized basophils (16, 17). It induces both 
aggregation of platelets and secretion of their content of vasoactive amines (17, 
footnote 2).  (b) C3 bound to particles such as zymosan (ZC3) also induces secre- 
tion from platelets having  a  C3 receptor,  e.g.,  those from the rabbit  (18).  (c) 
Antibody directed against the surface membrane of rabbit platelets which in the 
absence of complement, initiates noncytotoxic secretion of platelet constituents 
(19). The secretion induced by all three of these stimuli is inhibited by DFP (18- 
20).  Additional  stimuli examined were the potent platelet activators,  collagen 
and thrombin. The latter is in itself a serine protease. This group of five stimuli 
is representative of platelet stimuli in that it includes two particulate  stimuli 
(ZC3  and  collagen),  two  soluble  agents  (PAF  and  anti-platelet  antibody)  of 
differing molecular weights, and a proteolytic enzyme (thrombin). 
Experiments are described herein which were designed to determine whether 
the  secretory  response  of rabbit  platelets  to  five  different  stimuli  involves 
activation of cell bound serine proteases. Since this appeared to be so for at least 
four of them,  then we further attempted to determine whether each stimulus 
activates a different protease or whether one common enzyme is involved in the 
cell response. Since most of the pathway from stimulus to secretion is thought to 
be common for all the stimuli (1), this question also asks whether the protease is 
in  the  stimulus-specific  or  common  portions  of the  pathway.  The  evidence 
suggests that specific serine proteases which are activated by each stimulus are 
required for platelet secretion. 
2  Henson, P. M., and Z. G. Oades. 1976.  Activation of  platelets  by platelet-activating  factor 
(PAF) derived from IgE-sensitized basophils. III.  Characteristics of the aggregation  and its 
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Materials and Methods 
Platelets.  Blood was obtained from New Zealand white rabbits,  and  washed platelets were 
prepared  by a  modification of the technique of Ardlie et al.  (21),  as described earlier  (18  and 
footnote 2).  They were resuspended  in Tyrode's solution  containing 0.25%  gelatin but  lacking 
calcium  to  a  concentration  of  2.5  ×  109/ml.  To  examine  the  secretory  reaction,  exogenous 
[3H]serotonin  was  incorporated  into  the  platelets  before  washing  by  incubating  platelet-rich 
plasma with 0.6 ~Ci/ml [3H]serotonin binoxalate  (4.3  Ci/mmol, New England Nuclear,  Boston, 
Mass.) for 15 rain at 37°C. 
Secretion.  Platelets (0.1 ml containing 2.5  ×  l0  s platelets) were incubated with the stimulus 
(in 0.1  ml) and  inhibitor  (also generally in 0.1  ml) in a  final vol of 1 ml of Tyrode's solution 
containing gelatin and calcium for 15 min with shaking at 37°C. At the end of the incubation the 
tubes (12 x  75-ram polystyrene tubes, Lancer, Sherwood Medical Industries, St. Louis, Mo.) were 
chilled in ice and the platelets pelleted at 1,800g for 15 min in the cold. An aliquot (0.1 ml) of the 
supernate was removed and the radioactivity (secretion of serotonin) determined in a mixture of 
equal parts Aquasol (New England Nuclear) and toluene in a Beckman liquid scintillation counter 
(Beckman Instruments, Inc., Fullerten, Calif.). The secretion was expressed as a percentage of the 
total incorporated [3H]serotonin which could be detected in 0.1 ml of the platelet suspension lysed 
with 0.1% Triton x  100. The total counts thus measured generally ranged from 18 to 95 x  102 cpm. 
Background secretion (without stimulus) was always measured. It was generally from 1-5% and in 
most  cases  was  subtracted  from the stimulus-induced  secretion.  High concentrations  of a  few 
phosphonates  (e.g.,  the  long  chain  derivatives  of the p-nitrophenyl  ethyl  alkylphosphonate 
series when used above millimolar concentration) induced some secretion, and where this could 
not  be  avoided this  control  value  was  subtracted  from  the  release  found  with  stimulus  and 
phosphonate  together.  All reactions  were performed in  duplicate  or triplicate  and  the counts 
(which differed by less than 10%) averaged. The effect of the inhibitors was expressed as percent 
inhibition (see Results section). 
1.0  -  percent serotonin secreted in the presence of inhibitor  x  100 
percent serotonin secreted by the stimulus alone 
To compare different inhibitors of the phosphonate  series,  the pIso was calculated.  This is the 
negative logarithm (to the base 10) of the concentration of inhibitor which gives 50% inhibition of 
secretion. This figure was obtained from three or more separate experiments and expressed as the 
mean pIso ±  SEM. 
Stimuli.  PAF bound  to bovine serum  albumin  was  prepared  as  described  previously  (17). 
The activity is expressed as microliters of dialysed supernate from antigen-stimulated, sensitized 
leukocytes  2 or as  units  of PAF,  where  1 U  is that  amount  which induces  20%  secretion from 
2.5  x  l0  s platelets  in 1 ml. The gamma globulin fraction of goat anti-rabbit  platelet antibody 
(a-PAb) was prepared as described earlier (19 and footnote 2), and ZC3 was prepared by incubating 
extensively washed zymosan (Nutritional Biochemicals Corp., Cleveland, Ohio) with fresh rabbit 
serum (17 mg/ml) for 20 min at 30°C (18). The ZC3 was thoroughly washed and frozen in aliquots. 
A  control preparation  of zymosan  incubated  with  serum  in the presence of 10  mM EDTA  (to 
prevent binding of C3) did not stimulate secretion. Bovine thrombin was obtained from Parke, 
Davis & Co., Detroit, Mich.  Collagen was prepared by homogenization and sonication in phos- 
phate-buffered saline (PBS) of bovine tendon (Sigma Chemical Co., St. Louis, Mo.). All stimuli 
were  resuspendod  or  dissolved  in  PBS  and  where  appropriate,  protein  determinations  were 
performed by the Folin technique. 
Organophosphorus  Inhibitors.  DFP was obtained from Sigma Chemical Co. It was dissolved 
directly in Tyrode's gelatin immediately before use.  The p-nitrophenylethylphosphonate  esters 
were described earlier (2, 6, 13, 14, 22). The cyclohexyl phosphonofluoridate esters were described 
in references 7 and 8. The phosphonates were dissolved in dry propylene glycol at a concentration 
of 100 mM and kept at  -20°C.  Hydrolysis of the p-nitrophenyl compounds were determined by 
dissolving in phosphate  buffer and  immediately reading absorption  at 405  nM.  Concentrations 
were corrected for the degree of hydrolysis. It was previously ascertained that propylene glycol 
was a  suitable  solvent and  at the concentrations  used did not cause release of serotenin from 
platelets. At high concentrations of propylene glycol (above 5%, representing approximately 5 mM 1660  ACTIVATION OF STIMULUS-SPECIFIC  ESTERASES 
concentrations of the dissolved phosphonates) some inhibition of secretion was observed, but most 
of the phosphonates were used at concentrations  at which the solvent was without effect. The 
occasional use of slightly inhibitory concentrations  of propylene glycol was accompanied by an 
appropriate  positive control  (i.e.,  solvent  alone) so that accurate percent inhibition could be 
determined.  Phosphonates and DFP were hydrolysed by treating solutions of the inhibitors with 
0.1 M NaOH for 16 h and neutralizing with HC1. 
Pretreatment of Stimuli and Platelets.  Platelets were incubated for 15 or 30 min at 37°C with 
various concentrations of the inhibitors in Tyrode's gelatin without Ca**. They were then washed 
twice before testing the stimulus-induced  secretion.  Control platelets were similarly incubated 
with the appropriate  concentration  of propylene glycol or buffer alone. Stimuli were incubated 
with inhibitors and the DFP removed by overnight dialysis against PBS, or in the case of ZC3 by 
centrifugation  and washing.  Control preparations were incubated  without inhibitors and then 
dialyzed or washed. 
Results 
The Secretory Response of Platelets to Five Stimuli.  To examine most effec- 
tively the inhibitory action of the organophosphorus esterase (protease) inhibi- 
tors, concentrations of stimuli were determined, and the response was shown to 
be secretory in nature and not cytotoxic. Fig. 1 depicts the secretion induced by 
increasing  concentration  of thrombin,  a-PAb,  collagen,  ZC3,  and  PAF.  PAF 
produces an anomalous response in that the secretion is maximal at about 50- 
60%. This phenomenon has been described previously and probably results from 
the simultaneous induction of desensitization by this stimulus, which serves to 
limit the secretion (23). The cytoplasmic enzyme, lactic dehydrogenase (LDH), 
was not liberated by any of the stimuli, showing the noncytotoxic nature of  these 
secretory reactions. 
For the inhibition studies, concentrations of stimuli were employed to induce 
about 40% secretion of serotonin, i.e., on the linear portion of each dose response 
curve. Since exact percent release figures for a  given experiment could not be 
predicted,  it  was  important  to  show  that  the  percent inhibition  of secretion 
produced by the inhibitors was relatively independent of the amount of secre- 
tion. To do this different amounts of stimulus were incubated with platelets in 
the presence of a  constant concentration of DFP.  Data is shown in Table I  for 
PAF  and collagen and thrombin and was similar  over the range of secretion 
values employed (on the linear portion of the curves) for the other stimuli. 
It was also important to determine a  suitable incubation time for the reac- 
tions.  Although  the  rate  of secretion  induced  by  each  stimulus  varies,  the 
secretion is complete in 15 min at 37°C. An inhibitor such as DFP reduced the 
rate of secretion (Fig. 2). However, the secretion was again complete by 15 min 
and  no further effect was  seen if a  30-min  incubation  period was  employed. 
Accordingly, a  standard 15-min incubation period was used throughout. 
Inhibition of Secretion  with DFP.  To examine the potential role of serine 
proteases  in platelet  activation,  DFP was  examined for its  ability to inhibit 
secretion  by  all  five  stimuli  (Fig.  3).  Concentration-dependent  inhibition  of 
secretion was  observed for all  stimuli.  The range  of concentrations at which 
inhibition was  achieved,  however,  varied greatly with the  stimulus.  In fact, 
complete inhibition of collagen or anti-platelet antibody-induced secretion was 
not obtained. Nevertheless, the inhibition curves at lower degrees of inhibition 
were all parallel, pIso values (negative log10 of concentration of DFP to yield 50% 
inhibition) for ZC3, thrombin, and PAF were 4.7, 3.9, and 2.8, respectively. P.  M.  HENSON,  D.  GOULD,  AND  E.  L.  BECKER  1661  ~oo~  ~~ 
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FIG.  1.  Dose  response relationship  of the stimuli  for serotonin secretion from platelets. 
Platelets  (P,  2.5  ×  10  s in  1.0 ml) were incubated  with  the stimuli  for 15 min and  the 
secretion expressed as a percentage.  Lactic dehydrogenase (LDH, open symbols) was not 
released, indicating the noncytotoxic nature of the reactions. The concentrations of stimuli 
on the abscissa were as follows:  thrombin, mU, anti-platelet  antibody (a-PAb), micrograms 
immunoglobulin protein;  collagen, micrograms  protein;  ZC3, milligrams  Zymosan with 
bound C3; platelet-activating  factor (PAF), microliters  of supernate from antigen-stimu- 
lated,  IgE-sensitized  rabbit  basophils.  This preparation of  PAF yielded 67 U/ml or 15 ~I/U 
(see  Materials and Methods section). 
TABLE I 
Inhibitory  Action of DFP at Different Stimulus Concentrations 
Percent secretion of serotonin 
Stimulus  Percent 
Without  With DFP  inhibition 
DFP  (2 x 10  -3 M) 
PAF 
Collagen 
Thrombin 
25 ftl  64.8  37.4  42 
10/A  55.0  22.2  59 
5/A  27.8  11.9  57 
100 ~g  84.4  67.2  20 
40/~g  48.1  34.5  28 
20 ~g  11.5  8.8  23 
5 mU  47.3  12.8  72 
2.5 mU  20.3  6.3  69 
1.25 mU  7.5  2.9  62 
The  Requirement  for  a  Stimulus-Activatable  Protease.  To  determine 
whether  an  active  protease  was  present  on  the  platelets  which  were  being 
inhibited  by the  irreversible  organophosphorus inhibitor,  platelets  were pre- 
treated with concentrations of DFP and then washed.  As shown in Fig.  3,  no 
inhibition  of secretion  occurred under  these  circumstances.  Another possible 
explanation  for  the  effect  of DFP  is  that  the  stimuli  are  themselves  serine 
proteases responsive to the inhibitory action of DFP. That this is so for thrombin 
is depicted in Fig. 3.  Pretreatment of thrombin with DFP followed by dialysis 
completely abrogated its serotonin-releasing capacity. However, pretreatment 
of the  other  stimuli  with  DFP  did  not  prevent  their  subsequent  action  on 
platelets.  For  ZC3,  over  1/500  concentration of DFP  is  required  to  inhibit  if 
present during the reaction than if used to pretreat the stimulus on the plate- 1662  ACTIVATION  OF STIMULUS-SPECIFIC  ESTERASES 
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Fro.  3.  Inhibition of secretion by DFP.  Increasing concentrations of DFP were incubated 
in the reaction of stimulus and platelets  (closed symbols) or used to pretreat the platelets 
(open symbols) or the stimuli (hatched symbols). The platelets (P) and stimuli were washed 
or dialyzed after the pretreatment.  The figures represent the pIso for the respective stimuli. 
lets. These data suggest the involvement of a platelet serine protease which is 
activated by the stimulus and only then becomes inhibitable by DFP. 
Inhibition  of  Secretion  With  Cyclohexyl  Phenylalkylphosphonofluori- 
dates.  Experiments  with  the  phosphonate  inhibitors  were  initiated  to  (a) 
support the hypothesis of involvement of serine proteases in platelet secretion 
and  (b)  to  attempt  to  determine  whether  the  effect of the  different stimuli 
required the action of one or more different enzymes. 
The cyclohexyl phenylalkylphosphonofluoridates  were found to be the most 
effective inhibitors of the platelet secretion.  Fig. 4 depicts inhibition curves of 
these agents on the secretion induced by ZC3. The phenyl derivative was found 
to give 50% inhibition at 1.3  ×  10 -~ M.  It may be seen that all the curves are P.  M.  HENSON,  D.  GOULD,  AND E. L.  BECKER 
100- 
....  i,:[o-6 
y  / 
..... 
1663 
Molar Concentration  of inhibitor 
FIG.  4.  Inhibition of ZC3  induced secretion by cyclohexyl phenylalkylphosphonofluori- 
dates. The numbers represent the number of carbon atoms in the phenyl alkyl side chain, 
i.e.,  0  =  phenyl,  1  =  benzyl, 2  =  phenyl ethyl, and 3  =  phenylpropyl phosphonofluori- 
dates. The arrows indicate 50% inhibition from which the pIso was calculated. 
parallel,  suggesting an action on the same enzyme and allowing a  determina- 
tion of the pIso. From experiments such as this, the data presented in Fig. 5 was 
obtained. ZC3 and thrombin were inhibited by very low concentrations of these 
inhibitors.  However, a  clear distinction between the activity-structure profiles 
of the phosphonofluoridates in their inhibition of all five stimuli was found. This 
strongly  suggests  that  each  stimulus,  except possibly thrombin  (see below), 
activates a unique serine protease, exhibiting its own activity structure profile. 
As with DFP, the phosphonofluoridates were found to be much less effective if 
used to pretreat the platelets than if added to the reaction of stimulus with cells. 
In this instance the inhibitors were from 10 to 100-fold more effective if included 
in the reaction. 
Inhibition  of Secretion  with p-Nitrophenyl  Ethyl  Chloroalkylphosphonate 
Esters.  Inclusion of these inhibitors  in the reaction effectively prevented the 
secretion induced by all five stimuli  (Fig. 6). This series of inhibitors was most 
effective against collagen, especially those with longer side chains.  The chloro- 
hexyl derivative caused 50% inhibition at 5 × 10  -5 M (pIso = 4.32). The inhibitors 
were least effective against anti-platelet antibody-induced secretion. Distinctive 
activity structure profiles were observed for all stimuli, except ZC3 and throm- 
bin  the  action  of which  was  similar  and  was  maximally  inhibited  by the 
chloropentyl (n = 5) compound and minimally affected by the chloroheptyl (n = 
7) derivative. 
To  determine  whether  the  phosphonates  were  inhibiting  a  cell-dependent 
protease,  i.e.  an enzyme on the cell which was already active, rather  than  a 
stimulus-dependent protease, i.e. one which was activated by the stimulus, the 
platelets were pretreated with the inhibitors and then washed. Table II depicts 
the results with the chlorobutyl compound, although the other inhibitors gave 
similar  results.  Inclusion  Of the  inhibitor  in  the  reaction  was  much  more 
effective than if the platelets were pretreated. Again, action of the phosphonates 
on a  stimulus-activated esterase is suggested. 
Two other series of phosphonate  inhibitors  were studied,  the p-nitrophenyl 
ethyl phenylalkyl- and p-nitrophenyl  acetoxyphenylalkylphosphonates.  While 
these inhibitors were slightly less active than those shown in detail above, they 1664  ACTIVATION  OF STIMULUS-SPECIFIC  ESTERASES 
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FIG.  6.  Inhibition  of  platelet  secretion  by p-nitrophenyl  ethyl  chloroalkylphosphonate 
esters.  The results are expressed  as mean pIso ---  SEM  of three or more experiments. 
too were capable of distinguishing between the different stimuli and were more 
effective if included in the reaction mixture. 
Effect  of Nonphosphorylating  Phosphonates  and  of Hydrolyzed  Inhibi- 
tors.  The possibility that the inhibition was not due to phosphorylation of the 
active center of the putative platelet proteases was examined. The data in Table 
III compare the effect ofp-nitrophenyl ethyl pentylphosphonate which is a good P.  M.  HENSON,  D.  GOULD,  AND  E.  L.  BECKER 
TABLE  II 
Inhibition of Platelet Secretion by p-Nitrophenyl Ethyl Chlorobutyl- 
phosphonate Ester 
1665 
Inhibitor  present  dur- 
ing the  reaction 
Platelets  pretreated 
with the inhibitor  and 
washed 
pl  so 
Collagen  3.84  <2.0 
Anti-platelet  antibody  3.3  <2.0 
PAF  3.84  <2.0 
ZC3  3.4  3.0 
Thrombin  3.4  3.0 
TABLE III 
Lack of Inhibition by Nonphosphorylating  Compounds 
Inhibiter 
Percent inhibition of secretion 
ZC3  Thrombin  Collagen 
p-nitrophenylethyl pontylphosphonate (2.5 x  10  -4 M) (phosphorylating)  58 
Phenylethyl pentylphosphonate (2.5 x  10  _4 M) (poorly phosphorylating)  6 
54  38 
3  8 
Diisepropyl  phosphofluoridate (DFP) (1 x  10  -a M) (phosphorylating)  100  100  25 
Diisopropyl  methyl phosphate (DMP) (1 x  10  -3 M) (nonphosphorylating)  0  0  0 
phosphorylator  with  phenyl  ethyl  pentylphosphonate  which  phosphorylates 
very  poorly.  The  phenyl  phosphonates  are  much  less  effective  irreversible 
inhibitors  of serine esterases than  are the p-nitrophenyl  derivatives  (11).  The 
phenyl phosphonate was also much less effective in preventing serotonin secre- 
tion. Similarly, the nonphosphorylating diisopropyl methyl phosphate was com- 
pared with the phosphorylating  compound,  DFP,  and found to be completely 
ineffective as an inhibitor of platelet secretion. 
Another way of approaching the question of other actions of the phosphonates 
is to determine whether hydrolysis of the agents prevents their action  (8) and 
whether some of the activity is due to the products of hydrolysis. Table IV shows 
the ineffectiveness of the hydrolyzed compounds (including  DFP) and of prod- 
ucts  of the  hydrolysis  such  as p-nitrophenol  or  fluoride.  This  supports  the 
concept of the agents acting as irreversible serine esterase inhibitors. 
Phosphonate Inhibition of the Esterolytic Action of Thrombin.  The secretion 
from platelets which is induced by thrombin was also inhibited by these series of 
phosphonate  and fluoridate  inhibitors.  The exogenous serine protease in this 
system  could  be  acting  either  directly  on  some  protease-sensitive  substrate 
within the platelet or could itself activate a serine protease in or on the cell. In 
an attempt to distinguish between these possibilities we examined the activity- 
structure  profiles  of the  cyclohexyl phenylalkyl  phosphonofluoridates  on the 
hydrolysis of benzoyl-/-arginine ethyl ester (BAEe) by thrombin was examined. 
If the profile were different from that for the action of thrombin on platelets the 
activation of another  esterase within the platelet might be implicated.  Fig.  7 
depicts the hydrolysis of BAEe by 1 U of thrombin, measured by the increase in 
absorbance at 253 nm.  Cyclohexyl phenylethylphosphonofluoridate  effectively 
inhibited the enzyme in a  time-dependent fashion as expected. Addition of the 1666  ACTIVATION OF STIMULUS-SPECIFIC ESTERASES 
TABLE IV 
Lack of Inhibition by Hydrolyzed Compounds 
Inhibition 
Percent  inhibition  of  secretion 
ZC3  Thrombin  Collagen 
DFP (2  ×  10  -3 M)  100  100  39 
DFP hydrolyzed* (2  ×  10 -3 M)  0  0  0 
Cyclohexyl phenylpropyl (1  ×  10 -5 M)  100  100  48 
Cyclohexyl phenylpropyl hydrolyzed* (1  ×  10 -5 M)  13  0  0 
Propylene glycol  4  0  0 
Propylene glycol hydrolyzed*  4  0  0 
p-nitrophenol (5  ×  10  -4 M)  0  0  0 
Sodium fluoride (10  -3 M)  3  0  1 
* Treated with 0.1 M NaOH and then neutralized. 
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Fro.  7.  Inhibition of the esterolytic activity ofthrombin. 1 U ofthrombin was added to 1.5 
ml 1 raM BAEe in 0.15 M NaCl buffered to pH 7.6 with 0.01 M Tris at 37°C and the changes 
in OD at 253 nm determined on a strip recorder. Cyclohexyl phenylethylphosphonofluori- 
date was added at the start of the incubation or was preincubated with the enzyme for 10 
rain before addition of substrate. 
inhibitor concurrently with the enzyme and substrate was much less effective 
than preincubation  of the thrombin  with the inhibitor.  This may explain the 
relatively high concentration of the inhibitors required to inhibit the stimulus- 
activated  proteases  in  the  platelets,  since  this  experimental  circumstance  is 
essentially the same as that of concurrent addition of inhibitor,  enzyme,  and 
substrate. 
The  activity  structure  profiles  of the  phosphonofluoridates  in  inhibiting 
thrombin-induced serotonin secretion from platelets and thrombin-induced hy- 
drolysis of BAEe are compared in Fig. 8. They were found to be identical.  The 
absolute values of the pIso'S cannot be compared because of the 10-min preincu- 
bation of inhibitor and thrombin.  In the platelet experiments the phosphonates 
were apparently acting on the thrombin itself and not detectable on a thrombin- 
activated esterase. P.  M.  HENSON,  D.  GOULD,  AND  E.  L.  BECKER 
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FIG.  8.  Activity structure  profiles of the cyclohexyl phenylalkylphosphonofluoridates  in 
inhibiting the action of thrombin on platelets (secretion) or on BAEe (esterolysis). 
Discussion 
Induction of the secretory response in rabbit platelets by five different stimuli 
was prevented by organophosphorus inhibitors of serine proteases (esterases). 
The involvement of such enzymes in the platelet release reaction was thereby 
suggested.  In  addition,  the  data  support  the  concept of the  enzymes being 
stimulus-activatable proteases, since inhibition was only achieved by concur- 
rent addition of  the inhibitor and stimulus to the platelets and nonphosphorylat- 
ing or poorly phosphorylating analogues were inactive.  Finally,  the unique 
activity structure profiles found for the  phosphonate inhibition  of secretion 
induced by the different stimuli were highly suggestive of the requirement for a 
unique activatable platelet protease for each of the stimuli. 
The Requirement for an Activatable Serine Protease.  Stimulation of secre- 
tion from rabbit  platelets by collagen,  PAF,  anti-platelet antibody,  particle 
bound C3, and thrombin was in each case inhibitable by concurrent addition of 
organophosphorus inhibitors. DFP was effective against all five stimuli, but in 
most cases only at high concentrations. The p-nitrophenyl ethyl chloroalkyl- 
phosphonates and cyclohexyl phenylalkylphosphonofluoridates, however, were 
highly active in inhibiting the secretory response. Since the inhibition of serine 
esterases by these compounds is both  time and temperature dependent, the 
relatively high concentrations required in most cases for inhibition is readily 
explained. As depicted in Fig.  7,  concurrent addition of inhibitor to an active 
enzyme (thrombin) in the presence of its  substrate  is  an  inefficient way to 
prevent the cleavage of the substrate. And yet this is precisely the situation in 
the  cell,  where the  protease  is  presumably activated in  some  way by  the 
stimulus (see below) and then finds itself in the presence of both substrate (in 
this case an unknown substrate in the cell) and the inhibitor. The ability of, for 
example, cyclohexyl phenylphosphonofluoridate to inhibit ZC3-induced secre- 
tion with a pI~o of about 6.0 therefore indicates great potency and considerable 
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Before the existence of cell-associated proteases could be inferred, it was most 
important  to  eliminate  the  possible  action  of the  inhibitors  on  the  stimuli 
themselves. Pretreatment of ZC3, collagen, PAF, or a-PAb had no effect on their 
subsequent  action  on  platelets.  As  expected,  however,  the  serine  protease, 
thrombin,  was completely inhibited.  In  view of the  great  sensitivity of ZC3- 
induced secretion to inhibition by organophosphorus agents, the similarities of 
the  inhibition  profiles  to  those  of thrombin,  using  the p-nitrophenyl  ethyl 
chloroalkylphosphonates,  the possible peptidase activity of bound C3  (25),  and 
the method of preparation of ZC3 (i.e., incubation of zymosan with fresh serum, 
from  which  a  number  of proteases  could have  been  absorbed)  indicated  the 
special need for this control.  However, the action of ZC3 was not prevented by 
pretreatment  with DFP or phosphonates  and is not inhibited by the thrombin 
inhibitor  hirudin  (18).  Moreover,  the  inhibition  profiles with  the  phosphono- 
fluoridates for ZC3 and thrombin were found to be significantly different. 
It  is  also important  to  examine  the  possibility that  the  organophosphorus 
inhibitors are acting on the platelets in some way other than as serine esterase 
inhibitors.  A number of lines of evidence serve to render this possibility highly 
improbable.  The  most  likely  action  would  be  as  detergents.  However,  the 
compounds with the larger hydrophilic side chain would be expected to be more 
effective,  and  this  was  not  found  to  be  the  case.  In  addition,  the  different 
inhibitory  activities  of the  various  phosphonates  or  fluoridates  in  a  series 
against the different stimuli argue against this possibility as does the effective- 
ness of DFP itself. Further support for the involvement of the specific phospho- 
rylating action of the inhibitors came from examination of the nonphosphorylat- 
ing, diisopropyl methyl phosphate and the poorly phosphorylating phenyl ethyl 
pentylphosphonate.  These were found to be inactive  as inhibitors  when com- 
pared  with their  phosphorylating  counterparts,  DFP and p-nitrophenyl  ethyl 
pentylphosphonate.  Hydrolysis of the organophosphorus compounds prevented 
their  inhibitory  action,  indicating  that  the  complete  and  active  molecule  is 
required. It was also shown that the inhibition was not produced by the hydroly- 
sis products p-nitrophenol  or fluoride. 
If the protease or esterase that is being inhibited is in or on the platelet, the 
question now arises  (see reference 1) as to whether it is already activated (cell 
dependent) or is activated by the effect of the stimulus  (stimulus dependent). 
Pretreatment  of the platelets with the inhibitors  followed by washing did not 
prevent the subsequent activation of the cells by the stimuli.  Since these are 
irreversible  inhibitors  of serine  proteases  (12-14),  the  data  suggest  that  the 
enzymes involved in the secretory response of platelets are stimulus dependent. 
The  presumption  that  in  the  instances  studied  the  organophosphorus  com- 
pounds are acting as irreversible inhibitors is strongly supported by the demon- 
stration that the nonphosphorylating or poorly phosphorylating analogues are 
inactive.  The differences in pIso for phosphonates,  fluoridates, and DFP added 
concurrently with those when the cells were pretreated were found to vary with 
the stimuli and the inhibitor.  In some cases, the difference was more than 500- 
fold,  in  others  less  than  10-fold.  The  latter  circumstance  was  particularly 
evident when poorly inhibited stimuli were employed (e.g., anti-platelet anti- 
body) or when inhibitors with long side chains were examined. It is believed that P.  M.  HENSON,  D.  GOULD,  AND E.  L.  BECKER  1669 
the effect is in part due to absorption of the inhibitors, particularly if they have 
long hydrophobic side chains, by the platelet membranes so that they are not 
effectively washed out after pretreatment. Activation studies  with  [3H]DFP 
(Becker and Henson, unpublished observations) would support this contention. 
It is concluded, therefore, that the data overestimate the inhibitory effect of 
pretreatment of the platelets and that with all four stimuli studied the involve- 
ment of stimulus-activated proteases is strongly indicated. 
This probable  involvement of stimulus-activated proteases or esterases in 
platelet activation provides another example to support the hypothesis that such 
stimulus-activated proteases represent a general phenomenon, at least in the 
triggering of 'mediator cells' such as mast cells, basophils,  neutrophils, and 
lymphocytes (1). Mast cells have been shown by similar techniques to have 
stimulus-activated esterases which are required for secretion (2, 3). The anti-Ig- 
induced movement of B ]ymphocytes have also been demonstrated to require a 
stimulus-activated esterase (11), and there is suggestive evidence that this is 
true of human T lymphocyte-mediated  cytotoxicity (9). Neutrophil chemotaxis 
was found to involve both a stimulus-dependent and a cell-dependent esterase 
(6). In other cell processes, e.g. neutrophil phagocytosis (7) or mouse T-lympho- 
cyte cytotoxicity (8), cell-dependent esterases have been demonstrated, but con- 
clusive evidence for stimulus-dependent enzymes has not yet been presented. 
While secretion from rabbit platelets has been shown to involve predominantly 
stimulus-activated esterases, the concurrent requirements for a cell-dependent 
(i.e., previously activated) enzyme of this type, which is relatively resistant to 
inhibition by the phosphonates, cannot be completely excluded. 
Stimulus Specificity of the Activatable Proteases.  The data presented using 
three series ofp-nitrophenyl ethyl phosphonate inhibitors and one ofphosphono- 
fluoridates indicate that the effect of each stimulus was uniquely inhibited by 
these compounds. Activity-structure profiles for the series of inhibitors against 
the five stimuli were both characteristic and different for each stimulus. This 
was  particularly evident for the  cyclohexyl phenyalkylphosphonofluoridates 
which were the most inhibitory group of compounds tested. However, it was also 
seen with the p-nitrophenyl ethyl chloroalkylphosphonates as also with a group 
of p-nitrophenyl ethyl alkylphosphonates and  of p-nitrophenyl ethyl pheny- 
alkylphosphonates (for which the data were not presented). These results repre- 
sent strong evidence in support of the conclusion that each stimulus activates a 
unique serine protease which is then required for the secretory process. Other 
explanations for the effect  of different inhibitors, for example a differing solubil- 
ity in  the platelet  membrane, would not  account for the  unique  inhibition 
profiles for each stimulus. 
Thrombin is itself a  serine protease and exhibits its own unique profile of 
inhibition. The action of thrombin on the platelets might therefore be either to 
activate a platelet protease or perhaps to act on the intracellular substrate(s) of 
these putative proteases,  i.e.,  to act on the next stage in the sequence. The 
inhibition profile (phosphonofluoridates) for the esterolytic action of thrombin 
was identical with that for its secretion-inducing  action. At this time, therefore, 
these two possibilities cannot be distinguished. The unique profile does suggest 
that prothrombin on the platelets is not being activated by the other stimuli. 1670  ACTIVATION OF  STIMULUS-SPECIFIC  ESTERASES 
However, the similarities in the profile for thrombin and ZC3 exhibited by most 
of  the phosphonate series raised the question of ZC3 activation ofa prothrombin- 
like enzyme. Two lines of evidence suggest that this is not so.  (a) The inhibition 
profile of the cyclohexyl phenylalkylphosphonofluoridates for ZC3 and throm- 
bin  is  different.  (b)  Repeated  attempts  to  prevent  ZC3-induced release  by 
hirudin have been unsuccessful (see also reference 18). 
The substrate(s) for these proteases in the platelet are not known. Other areas 
still to be investigated include the site of the enzymes and their position in the 
sequence of events leading from stimulus to secretion (stimulus-secretion cou- 
pling).  Preliminary data (24,  26,  and, to be published) suggest that the DFP- 
inhibitable steps in the secretion sequence are the earliest that can be detected. 
This would be compatible with the idea of an early stimulus-specific step or 
steps which then initiate a  common pathway resulting in  secretion (1).  The 
ability to induce stimulus-specific desensitization of platelets (23) also supports 
this concept and raises the possibility that the desensitization involves decay or 
inhibition of the specific activated esterase.  A  similar phenomenon has been 
described in neutrophils where the desensitization was prevented by low molec- 
ular weight amino acid esters (27). 
The earliest step in the sequence is presumably the binding of the stimulus to 
its receptor.  The question arises as to how the stimulus-receptor interaction 
could activate the protease. The simplest hypothesis equates the receptor with 
the precursor protease since any other mechanism involves two highly specific 
steps, i.e., stimulus-receptor interaction and the interaction of specific receptor 
with specific protease. This possibility will only be proven by isolation of the 
receptor and the protease as a single entity. Experiments are proceeding in this 
direction. Indirect support for the hypothesis, however, comes from the demon- 
strated mechanism of activation of two plasma mediation systems. The comple- 
ment and intrinsic coagulation systems are initiated by activation of the precur- 
sor serine proteases C1 and Hageman factor, respectively. The activation may 
involve a conformational change in the enzyme to expose an active site. This can 
then be inhibited by DFP or phosphonate esters (2, 28). By limited proteolysis 
the enzymes then cleave and activate the next components in the system, C4 and 
Factor XI, respectively. It is proposed that a  similar system may exist in the 
platelets  (and other cells).  The stimulus,  which is usually at least divalent, 
could bind to the receptor (which is close to or identical with the precursor serine 
protease)  and  then  conformationally alter  the  protease  to  expose  its  active 
center. A  possible role for cross-linking of receptors (aggregation of receptor) 
could also be explained in this manner. The enzyme could then initiate the 
secretory process within the platelet. 
Direct proof of this  hypothesis will  require  isolation  of the  esterases  and 
desensitization of their activation mechanism and their effect in the cell. How- 
ever, indirect evidence is accumulating. Thus stimulus-dependent binding of 
[3H]DFP to C5a-stimulated neutrophils has been found (Becker and Henson, 
unpublished observations). A minimum of 1,000 molecules of protease per cell 
was calculated. Moreover, the platelet secretion can be inhibited by low molecu- 
lar  weight  amino  acid  esters  (Henson,  Landes,  and  Becker,  manuscript  in 
preparation). As with the phosphonates, different esters optimally inhibit differ- P.  M.  HENSON,  D.  GOULD,  AND  E.  L.  BECKER  1671 
ent  stimuli.  Taken  together  these  experiments  strongly suggest  a  role  for 
unique stimulus-specific activatable proteases in platelet secretion. 
Summary 
The effect of organophosphorus inhibitors of serine esterases  (proteases) on 
secretion from washed rabbit platelets was examined. Five noncytotoxic stimuli 
were employed: collagen, thrombin, heterologous anti-platelet antibody (in the 
absence of complement), rabbit C3 bound to zymosan, and platelet activating 
factor derived from antigen-stimulated, IgE-sensitized rabbit basophils. 
Diisopropyl phosphofluoridate, three series of p-nitrophenyl ethyl phospho- 
nates,  and  a  series  of cyclohexyl phenylalkylphosphonofluoridates were  all 
found to be inhibitory to the platelet secretion. These are irreversible inhibitors 
of serine  proteases  but  in  this  system were  only inhibitory if added to  the 
platelets concurrently with the stimuli. Pretreatment of either the platelets or 
the stimuli with the inhibitors followed by washing, was without effect on the 
subsequent reaction.  This  suggested the involvement of stimulus-activatable 
serine proteases in the secretory process. The concept was supported by finding 
that  nonphosphorylating phosphonates or  hydrolyzed phosphonates  or  phos- 
phonofluoridates were without inhibitory action. 
The effect of a  series of phosphonates or phosphonofluoridates in inhibiting 
each stimulus exhibited a unique activity-structure profile. The demonstration 
of such unique profiles with four series of inhibitors for each of the five stimuli 
was interpreted as demonstrating that a specific activatable serine protease was 
involved in the platelet secretory response to each stimulus. 
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